Dupilumab-Associated Sezary Syndrome

Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamp, Austin, Hanson, Jamie, Alhatem, Albert, Schwartz, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564184/
https://www.ncbi.nlm.nih.gov/pubmed/37822402
http://dx.doi.org/10.4103/ijd.ijd_580_22
_version_ 1785118452077297664
author Hamp, Austin
Hanson, Jamie
Alhatem, Albert
Schwartz, Robert A.
author_facet Hamp, Austin
Hanson, Jamie
Alhatem, Albert
Schwartz, Robert A.
author_sort Hamp, Austin
collection PubMed
description Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.
format Online
Article
Text
id pubmed-10564184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-105641842023-10-11 Dupilumab-Associated Sezary Syndrome Hamp, Austin Hanson, Jamie Alhatem, Albert Schwartz, Robert A. Indian J Dermatol Case Report Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10564184/ /pubmed/37822402 http://dx.doi.org/10.4103/ijd.ijd_580_22 Text en Copyright: © 2023 Indian Journal of Dermatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Hamp, Austin
Hanson, Jamie
Alhatem, Albert
Schwartz, Robert A.
Dupilumab-Associated Sezary Syndrome
title Dupilumab-Associated Sezary Syndrome
title_full Dupilumab-Associated Sezary Syndrome
title_fullStr Dupilumab-Associated Sezary Syndrome
title_full_unstemmed Dupilumab-Associated Sezary Syndrome
title_short Dupilumab-Associated Sezary Syndrome
title_sort dupilumab-associated sezary syndrome
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564184/
https://www.ncbi.nlm.nih.gov/pubmed/37822402
http://dx.doi.org/10.4103/ijd.ijd_580_22
work_keys_str_mv AT hampaustin dupilumabassociatedsezarysyndrome
AT hansonjamie dupilumabassociatedsezarysyndrome
AT alhatemalbert dupilumabassociatedsezarysyndrome
AT schwartzroberta dupilumabassociatedsezarysyndrome

Ejemplares similares